Barclays
THRD

Barclays’s Third Harmonic Bio THRD Stock Holding History

Barclays’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56,905
Closed -$309K – 5730
2025
Q2 		$309K Buy
56,905
+21,874
+62% +$109K ﹤0.01% 4036
2025
Q1 		$122K Sell
35,031
-7,457
-18% -$36.2K ﹤0.01% 4324
2024
Q4 		$437K Buy
42,488
+13,476
+46% +$168K ﹤0.01% 3907
2024
Q3 		$393K Buy
29,012
+18,710
+182% +$232K ﹤0.01% 3921
2024
Q2 		$134K Sell
10,302
-5,730
-36% -$70.9K ﹤0.01% 3773
2024
Q1 		$151K Sell
16,032
-10,704
-40% -$104K ﹤0.01% 4252
2023
Q4 		$293K Buy
26,736
+23,226
+662% +$184K ﹤0.01% 4227
2023
Q3 		$22.4K Sell
3,510
-450
-11% -$2.75K ﹤0.01% 4153
2023
Q2 		$19K Sell
3,960
-2,514
-39% -$12K ﹤0.01% 4144
2023
Q1 		$26.7K Buy
6,474
+3,080
+91% +$13.1K ﹤0.01% 4597
2022
Q4 		$14.6K Sell
3,394
-25,356
-88% -$424K ﹤0.01% 4871
2022
Q3 		$546K Buy
+28,750
New +$518K ﹤0.01% 2649

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Barclays's THRD Position: Q3 2025 in Review

Barclays sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 56,905 shares — an estimated $309K sold.

Barclays first reported a position in THRD in Q3 2022 and held it in 12 quarters. The position peaked at $546K in Q3 2022. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Barclays reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 56,905 Third Harmonic Bio shares in Q3 2025, an estimated $309K.
  • Barclays first reported a position in Third Harmonic Bio in Q3 2022 and held it in 12 quarters.
  • Barclays's Third Harmonic Bio position peaked at $546K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.